scroll to top of page

Clinical Trials

Contact Information

Jennifer England, RN, BSN

Clinical Trials Office
Thompson Cancer Survival Center
1915 White Avenue
Knoxville, TN 37916
Phone: (865) 331-1812

Monday – Friday, 8:00 am – 4:30 pm

Clinical trials are research studies designed to discover new ways to treat different cancers, and directly impact the number of new therapies and treatments available to fight cancer. Today’s trials are tomorrow’s standard of cancer care.

Thompson was the first to bring cancer clinical trials to East Tennessee more than 25 years ago. Our oncologists are certified to participate in clinical trials and work with multiple cancer research groups to bring innovative treatments to East Tennessee. In addition, we partner with pharmaceutical companies to give our patients access to new treatments not otherwise available. We offer clinical trials because they often lead to better ways to diagnose, treat, and prevent cancer, allowing people to live healthier and longer lives. Ask your doctor if a clinical trial might be right for you.

Brain

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Breast

Protocol NumberNCT NumberSummaryPrincipal Investigator
NSABP  B-51/RTOG 1304NCT01872975A study for women with early stage breast cancer to determine if giving less radiation is as effective as traditional radiation in patients who have had a very good response to chemotherapy received prior to surgery.  Grant Clark, MD
SWOG S1207/NSABP B-53NCT01674140A study for high-risk HER2 negative, hormone receptor-positive breast cancer to determine if adding a pill (Everloimus) to standard hormonal treatment after patients have received their chemotherapy and/or radiation therapy, will decrease the risk of breast cancer returning. Wenquing Zhang, MD

Gastrointestinal

Protocol NumberNCT NumberSummaryPrincipal Investigator
NSABP C-13 (Colon)NCT02664077A study for Stage III colon cancer to determine if taking a pill, Regorafenib, after patients have completed their chemotherapy and surgery will decrease the risk of colon cancer returning.  Wenquing Zhang, MD

Genitourinary

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Gynecologic

Protocol NumberNCT NumberSummaryPrincipal Investigator
NRG-GY004NCT02446600A study for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer to determine if taking a pill, Olarparib, by itself or in combination with another pill, Cediranib, is more effective than standard chemotherapy.  Brook Saunders, MD
NRG-GY005NCT02502266A study for patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer that has recurred within six months of treatment or progressed while on treatment, to determine if taking a pill, Cediranib, by itself or taking a different pill, Olarparib, by itself or if taking the combination of both pills is more effective than standard chemotherapy.  Brook Saunders, MD

Head and Neck

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Leukemia/Lymphoma

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Lung: Non-Small Cell

Protocol NumberNCT NumberSummaryPrincipal Investigator
SWOG S1400NCT02154490A study for patients that have been previously treated for advanced stage squamous cell lung cancer. Cancer tissue is analyzed and matched to be treated by new therapies like targeted therapy or immunotherapy. Numerous treatments are available depending on test results. Everett Ribakove, MD
EMR100070-005 (Javelin)NCT02576574A study for patients with advanced non-small cell lung cancer that has not been treated yet to determine if Avelumab (immunotherapy) is more effective than standard chemotherapy.  Wenquing Zhang, MD

Lung: Small Cell

Protocol NumberNCT NumberSummaryPrincipal Investigator
CALGB 30610NCT00632853A study for limited stage small cell lung cancer to compare two different ways to give radiation therapy to see which is more effective. In addition, every patient will get chemotherapy with Cisplatin and Etoposide, which is standard treatment for this type of lung cancer. Grant Clark, MD
NRG-CC003NCT02635009A study for patients with limited or extensive stage small cell lung cancer comparing two different ways of giving whole brain radiation to prevent cancer from metastasizing in the brain and to see which is more effective and has less side effects. Grant Clark, MD

Melanoma

Protocol NumberNCT NumberSummaryPrincipal Investigator
EA6134NCT02224781A study to determine which is the best sequence (targeted therapy followed by immunotherapy, or immunotherapy followed by targeted therapy) for treating patients with advanced BRAF positive melanoma. The medications include: Dabrafenib, Trametinib, Ipilimumab, and Nivolumab. Wenquing Zhang, MD
EA6141NCT02339571A study to determine if adding an injection (Leukine) will make treatment with immunotherapy (Ipilimumab + Nivolumbab) more effective for advanced melanoma. Everett Ribakove, MD

Multiple Myeloma

We are currently working with our research partners to increase the number of available trials. Please check back frequently for updates.


Recurrent Tumors, Lymphomas, and Multiple Myeloma

Protocol NumberNCT NumberSummaryPrincipal Investigator
EAY 131 MATCHNCT02465060A study to test more than 25 different treatments for patients with recurrent or rare cancers with a molecular profile that “matches” a targeted therapy. Wenquing Zhang, MD